Plain-English translation of NCT05361603 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hepatitis C research guide →This research is testing whether rapid screening tests—quick blood tests you can do outside a hospital—can successfully identify hepatitis B, hepatitis C, and HIV in people who use drugs. The study also uses a special ultrasound device called FibroScan to check liver health. The goal is to make screening easier and more acceptable by bringing these tests to community spaces where people already receive care.
People who use drugs often have higher risks of hepatitis and HIV but may avoid traditional hospitals or clinics. This study exists to figure out whether offering quick, simple screening in community settings—rather than formal medical facilities—makes it easier for people to get tested and find out their status early.
You likely qualify if…
You likely don't qualify if…
You would come to a screening day at a community facility (not a hospital). A nurse would offer you one or more quick blood tests and a brief ultrasound of your liver, all done on site. A doctor would then meet with you in a private space to discuss your results and explain what they mean. You'll receive written results to take home, and if needed, the doctor will help you understand next steps for your health.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
France
Enrollment target
~1,500 participants
Started
May 2017
Primary completion
December 2022
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2022.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Marilyne DEBETTE-GRATIEN, MD
Hôpital Dupuytren
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.